近日，海淀侵入式脑机接口领军企业智冉医疗宣布完成3亿元人民币A+轮融资。本轮融资由中科创星领 投，老股东君联资本、北京市医药健康产业投资基金、IDG资本、顺为资本、联想创投、元生创投、红 杉中国、美团龙珠、BV百度风投、杏泽资本、佳银资本持续跟投。 左：高通量可拉伸柔性电极；右：《自然・电子学》官网发布截图 除此之外，智冉医疗还实现了其余关键技术底座的全面突破：其国产神经信号采集芯片仅有硬币大小， 功耗较传统芯片直降75%；深度神经网络解码算法，依托海量神经元脑电数据进行训练，可实现高精度 的实时解码；配套的高效率、高精度智能化电极植入机器人，则打通了高通量侵入式脑机接口技术大规 模临床应用的"最后一公里"。 值得关注的是，这是智冉医疗在半年内完成的第二轮融资，短时间内连续获得资本青睐，充分印证了市 场对其在侵入式脑机接口赛道技术实力与发展潜力的双重认可。据悉，本轮所募资金将主要用于推进大 规模临床试验与高通量柔性脑机接口产品迭代，加速该技术向临床应用落地。 当前，全球脑机接口产业已进入技术分化与临床转化的关键窗口期，侵入式、半侵入式、非侵入式三大 技术路线呈现差异化竞争格局。其中，侵入式路线凭借神经信号采集 ...

近日，国内侵入式脑机接口领军企业智冉医疗宣布完成3亿元人民币A+轮融资。本轮融资由中科创星领 投，老股东君联资本、北京市医药健康产业投资基金、IDG资本、顺为资本、联想创投、元生创投、红 杉中国、美团龙珠、BV百度风投、杏泽资本、佳银资本持续跟投。 值得关注的是，这是智冉医疗在半年内完成的第二轮融资，短时间内连续获得资本青睐，充分印证了市 场对其在侵入式脑机接口赛道技术实力与发展潜力的双重认可。据悉，本轮所募资金将主要用于推进大 规模临床试验与高通量柔性脑机接口产品迭代，加速该技术向临床应用落地。 从创立之初，智冉就坚定地走侵入式脑机接口技术路线，一方面是因为团队在侵入式脑机接口底层技术 拥有深厚的技术积累；另一方面，是基于对行业终局的深刻认知。脑机接口的未来是要实现人类大脑与 外部设备之间高带宽的信息交互，从而将脑机接口从一种'弥补缺陷'的辅助工具，进化为人类通往高效 人机共生的核心底层技术，而只有侵入式脑机接口的路线能够实现这一跨越。 当前，植入式脑机接口已然形成了两种技术路线：半侵入式脑机接口和侵入式脑机接口。两者的本质区 别在于电极与脑组织的物理位置关系，这直接决定了神经信号的质量与应用上限。半侵入式 ...

Core Viewpoint - The article discusses the recent advancements and funding in the invasive brain-computer interface (BCI) sector, particularly focusing on the company "Zhiran Medical," which has completed a 300 million RMB A+ round of financing to enhance clinical trials and product iterations [2]. Group 1: Company Overview - Zhiran Medical has established a systematic layout in the upstream and midstream of the invasive BCI industry chain, focusing on core technology development and large-scale production [3][6]. - The company has made significant breakthroughs in key technologies, including flexible electrodes, neural chips, decoding algorithms, and electrode implantation robots, creating a complete industrial closed loop [3][6]. Group 2: Technological Advancements - Zhiran Medical's recent innovation includes a stretchable high-throughput flexible electrode that addresses issues of traditional linear electrodes, enhancing signal collection and biomechanical compliance [4][6]. - The company's neural signal acquisition chip is coin-sized and has reduced power consumption by 75% compared to traditional chips, while the deep neural network decoding algorithm allows for high-precision real-time decoding [6]. Group 3: Clinical Applications - By 2025, Zhiran Medical successfully completed the clinical implantation of the first domestic invasive BCI product with over 100 channels, validating its safety and effectiveness [6]. - The company plans to initiate large-scale clinical registration for its over 100-channel invasive BCI product in 2026, accelerating its clinical application [6]. Group 4: Industry Positioning - As a leading innovator in the domestic invasive BCI field, Zhiran Medical aligns with China's "14th Five-Year Plan" for future industry development and responds to national calls for independent innovation in cutting-edge technologies [7].